Rhumbline Advisers boosted its holdings in Becton Dickinson and Co (NYSE:BDX) by 23.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 443,389 shares of the medical instruments supplier’s stock after buying an additional 85,616 shares during the quarter. Rhumbline Advisers’ holdings in Becton Dickinson and were worth $94,912,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Becton Dickinson and by 30.8% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 185,490 shares of the medical instruments supplier’s stock valued at $39,708,000 after purchasing an additional 43,730 shares in the last quarter. Levin Capital Strategies L.P. boosted its stake in shares of Becton Dickinson and by 0.9% during the fourth quarter. Levin Capital Strategies L.P. now owns 63,040 shares of the medical instruments supplier’s stock valued at $13,494,000 after purchasing an additional 535 shares in the last quarter. HC Financial Advisors Inc. acquired a new stake in shares of Becton Dickinson and during the fourth quarter valued at about $2,456,000. Shell Asset Management Co. acquired a new stake in shares of Becton Dickinson and during the fourth quarter valued at about $11,069,000. Finally, Arizona State Retirement System boosted its stake in shares of Becton Dickinson and by 34.1% during the fourth quarter. Arizona State Retirement System now owns 109,595 shares of the medical instruments supplier’s stock valued at $23,460,000 after purchasing an additional 27,847 shares in the last quarter. 75.56% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently commented on the company. Morgan Stanley lifted their price target on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. Piper Jaffray Companies reissued an “overweight” rating and set a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a research note on Tuesday, February 6th. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price target on the stock in a research note on Friday, January 19th. Bank of America reissued a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a research note on Friday, January 19th. Finally, Citigroup raised Becton Dickinson and from a “sell” rating to a “neutral” rating in a research note on Friday, January 5th. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus target price of $237.27.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the company earned $2.33 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. research analysts predict that Becton Dickinson and Co will post 10.94 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a dividend of $0.75 per share. The ex-dividend date is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.35%. Becton Dickinson and’s dividend payout ratio (DPR) is 229.01%.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of Becton Dickinson and stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the sale, the director now directly owns 295,753 shares in the company, valued at $64,420,918.46. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.00% of the stock is owned by company insiders.
WARNING: This piece of content was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.com-unik.info/2018/02/18/becton-dickinson-and-co-bdx-shares-bought-by-rhumbline-advisers.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.